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Abstract
Butyrate, a fermentation product of fiber in the colon, acts as a histone deacetylase inhibitor (HDACi) and induces apoptosis
in colon cancer (CC) cells in vitro. We have reported that the apoptotic effects of butyrate are dependent upon the
hyperactivation of the Wnt/beta-catenin pathway. However, prolonged exposure of CC cells to increasing concentrations of
butyrate results in the acquisition of resistance to the Wnt/beta-catenin- and apoptosis-inducing effects of this agent, as
well as cross-resistance to structurally different HDACis. Here we report that one mechanism whereby HDACi resistance
arises is through the increase of beta-catenin-independent (noncanonical) Wnt signaling. Compared to HDACi-sensitive
HCT-116 CC cells, HDACi-resistant HCT-R cells exhibit higher levels of AKT/PKB cell survival signaling, which is in part
induced by WNT5A and its receptor ROR2. The induction of AKT signaling by HDACis is also detected in other CC cell lines,
albeit to a lesser extent than in the drug-resistant HCT-R cells. The observations suggested that the apoptotic effect of
butyrate and other HDACis in CC cells can be augmented by inhibitors of pAKT. In agreement with the hypothesis, the
combination of MK2206, a pAKT inhibitor, and a HDACi (butyrate or LBH589) induced higher apoptosis in CC cells compared
to each agent alone. The exposure to both agents also re-sensitized the HCT-R cells to apoptosis. Finally, the concept of
simultaneously inducing canonical Wnt activity and suppressing AKT signaling was translated into a combination of diet-
derived agents. Diet-derived pAKT inhibitors (caffeic acid phethyl ester, sulforaphane, dilallyl trisulfide) suppressed the
butyrate-induced levels of pAKT, and increased the apoptotic effects of butyrate in both drug-sensitive and drug-resistant
CC cells. Our findings can be translated into (a) CC therapy employing combinations of synthetic HDACis and inhibitors of
pAKT, as well as (b) CC prevention based upon diets that result in sufficient amounts of butyrate and pAKT inhibitors.
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Introduction
Beta-catenin - dependent (canonical) Wnt signaling is initiated
by the binding of Wnt ligands to their cell surface receptors, and
this binding triggers a cascade of intracellular events leading to the
accumulation of Ser-37/Thr-41 dephosphorylated beta-catenin.
The dephosphorylated beta-catenin is transcriptionally active, and
it forms complexes with LEF/TCF proteins to control the
expression of hundreds of genes [1–3]. The constitutive activation
of Wnt signaling due to mutations in its components, APC and/or
beta-catenin, promotes tumorigenesis in the colon [4–7], and such
mutations are characteristic of the majority of colon cancers (CC).
We have observed that CC cells with mutations in components of
the canonical Wnt signaling hyper-induce this pathway in the
presence of histone deacetylase inhibitors (HDACis), such as
butyrate (a fermentation product of fiber in the colon), SAHA,
MS275, and trichostatin A [8,9]. These HDACis induce apoptosis
in CC cells, and the apoptotic levels are dependent upon the fold
change in canonical Wnt activity: CC cells that exhibit low
induction of Wnt/catenin signaling in the presence of HDACis are
relatively resistant to the apoptotic effects of the agents; however,
cells that undergo significant activation of canonical Wnt signaling
are highly sensitive to apoptosis [8]. We have established that the
increase in Wnt/catenin activity in butyrate-treated CC cells
precedes the apoptotic event since (a) the inhibition of apoptosis by
a general caspase inhibitor does not abrogate the increase in Wnt/
catenin activity (unpublished data), and (b) flow cytometry–sorted
cell fractions with high canonical Wnt signaling consist of both live
and apoptotic cells; however, if apoptosis were a prerequisite for
induction of Wnt activity, all cells with high Wnt activity should
have been apoptotic [8]. The direct relationship between the fold
induction of Wnt/catenin activity and the degree of apoptosis was
observed in analyses of ten human CC cell lines exposed to
butyrate, and this relationship is causative since: (a) cells expressing
inducible dominant negative TCF4, which suppresses Wnt/
catenin signaling, exhibit decreased apoptosis in the presence of
butyrate [8], and (b) flow cytometry-sorted cell fractions with high
canonical Wnt activity have a higher ratio of apoptotic to live cells
than cell fractions with low levels of canonical Wnt activity [8].
The finding that hyper-activation of Wnt/beta-catenin signaling
results in high levels of apoptosis [8,9] is consistent with the reports
that fold changes in signaling pathways, rather than absolute levels
of signaling, elicit significant physiological response from cells [10–
12].
Through analyses of ten human CC cell lines, we have found
that HCT-116 cells respond to butyrate and other HDACis with
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apoptosis [8]. However, by gradual exposure of HCT-116 cells to
increasing concentrations of butyrate, we derived butyrate-
resistant HCT-R cells. These cells grow in the presence of
5 mM butyrate, a concentration that induces high levels of
apoptosis in the parental HCT-116 cells [9]. HCT-R cells are also
cross-resistant to structurally different HDACis, such as TSA, MS-
275, SAHA, and LBH589 [9]. Since we have established that (1)
the apoptotic outcome in CC cells is dependent upon the
induction of canonical Wnt activity [8], and (2) the hyper-
activation of canonical Wnt signaling in butyrate-treated CC cells
is in part initiated at the ligand-receptor level [9], we posited that
the drug-sensitive and drug-resistant CC cells differ in the
expression of WNT ligands, receptors, and/or positive and
negative modulators of Wnt/catenin signaling at the ligand-
receptor level [8,9]. In the present report we have investigated
these possibilities, and found that CC cells survive exposure to
butyrate or other HDACis by decreasing canonical Wnt signaling
and increasing beta-catenin - independent (noncanonical) Wnt
signaling.
Results
Increased expression of mediators of noncanonical Wnt
signaling in HDACi-resistant CC cells
We have previously reported that the HDACi-resistant
phenotype of HCT-R cells is not due to decreased acetylation of
histone proteins, but rather to the inability of the cells to hyper-
induce canonical Wnt signaling to the same extent as the parental
HDACi-sensitive HCT-116 cells [9]. Our findings suggested that
the suppression of Wnt/catenin activity in HDACi-resistant cells is
due to the changed expression of Wnt ligands, their receptors,
and/or modulators of Wnt signaling at the ligand-receptor level
[9]. To investigate this possibility, we analyzed the expression
profiles of mock- and butyrate-treated HCT-116 (HDACi-
sensitive) and HCT-R (HDACi-resistant) cells by Wnt-specific
PCR arrays (SA Biosciences). The analyses revealed that upon
exposure to 5 mM butyrate, HCT-116 and HCT-R cells
significantly increased the expression of WNT5A and WNT11
mRNA (data not shown), and we have confirmed this change in
expression at the protein level (Fig. 1A). Compared to HCT-116
cells, HCT-R cells expressed higher levels of both ligands, and the
presence of secreted WNT5A and WNT11 in tissue culture media
conditioned by CC cells was confirmed (Fig. 1A)
Dependent upon the receptor context, WNT5A and WNT11
induce either canonical or noncanonical Wnt signaling [13–17].
Since WNT5A induces noncanonical Wnt activity in the presence
of the receptor ROR2, we analyzed the expression of ROR2 in
the two CC cell lines. Western blot analyses revealed that both cell
types expressed ROR2; however, HCT-R cells exhibited higher
levels of ROR2 than the HDACi-sensitive HCT-116 cells (Fig. 1A).
Therefore, it is possible that WNT5A functions as a noncanonical
ligand in butyrate-treated cells, and that HCT-R cells exhibit
higher levels of noncanonical Wnt signaling than HCT-116 cells.
To ascertain the effects of WNT5A and ROR2 on Wnt activity,
we co-transfected HCT-116 and HCT-R cells with transcriptional
reporters for Wnt/beta-catenin signaling (TopFlash or FopFlash)
and siRNAs to WNT5A or ROR2. The decreased expression of
WNT5A and ROR2 in HCT-116 cells increased Wnt/beta-
catenin transcriptional activity in a statistically significant manner
(Fig. 1B). Butyrate-treated HCT-116 cells with suppressed ROR2
and WNT5A expression increased their levels of canonical Wnt/
catenin activity to 233.0619.8 and 161.0632.0 compared to the
control-transfected cells (94.8610.8), P,0.05, In mock-treated
HCT-R cells, the suppression of ROR2 and WNT5A expression
did not significantly alter Wnt transcriptional levels compared to
those in cells transfected with control siRNA (17.464.6 and
12.861.8, compared to 15.363.7 in control cells, P.0.05)
(Fig. 1C). However, in butyrate-treated HCT-R cells, the
suppression of ROR2 and WNT5A expression resulted in
significantly higher levels of canonical Wnt transcriptional activity,
compared to cells transfected with control siRNA (60.2612.5 and
53.168.4 compared to 31.267.9 in control cells, P,0.05)
(Fig. 1C). Therefore, WNT5A and its receptor ROR2 counteract
the induction of Wnt/beta-catenin activity in butyrate-treated
HCT-116 and HCT-R cells.
This conclusion was supported by the results from the
overexpression of WNT5A in HCT-116 cells. HCT-116 cells,
which express lower levels of WNT5A than HCT-R cells (Fig. 1A),
were co-transfected with the Wnt/beta-catenin reporters and an
empty vector, or a WNT5A expression vector. The cells co-
transfected with an empty vector increased their Wnt/beta-catenin
activity (TopFlash/FopFlash) from 5.261.1 to 62.269.3; whereas,
the cells overexpressing WNT5A increased their Wnt/beta-
catenin activity from 3.760.1 to 13.260.3 (Fig. 1D). The
difference in Wnt/beta-catenin transcriptional activity between
control- and WNT5A-transfected cells in the presence of butyrate
was statistically significant (P,0.05).
Since the silencing of ROR2 expression in HCT-R cells resulted
in higher levels of Wnt/beta-catenin signaling, and we have
previously observed that the higher induction of Wnt/beta-catenin
in CC cells corresponds to higher sensitivity of the cells to the
effects of butyrate [8], we analyzed the clonal growth of HCT-R
cells nucleofected with control siRNA or ROR2 siRNA. In the
absence of butyrate, the control siRNA- and ROR2 siRNA-
transfected cells exhibited a slight, but statistically significant,
difference in clonal growth (75.361.4% versus 67.663.4%,
P,0.05). In the presence of butyrate, the difference in clonal
growth ability was more pronounced; control-nucleofected HCT-
R cells exhibited clonal growth of 71.363.8% and ROR2 siRNA–
nucleofected cells exhibited 51.465.5% of clonal growth (Fig. 1E).
Induction of the AKT/PKB survival pathway by WNT5A
and ROR2 in CC cells
The increase in WNT5A expression in butyrate-treated HCT-
116 and HCT-R cells prompted a search for downstream effectors
of the ligand. Several noncanonical WNT5A-induced pathways
have been identified, and at least two of these are ROR2-
dependent: the phosphatidylinositol-3 kinase (PI3-K)/AKT sig-
naling triggered by the phosphorylation of AKT kinase [18-20],
and the JNK signaling pathway [21–23]. Consistent with these
reports, we observed that Serine473-phosphorylated AKT (pAKT)
is expressed at higher levels in HDACi-resistant HCT-R cells
compared to HCT-116 cells, and in both cell lines, exposure to
butyrate increased the levels of pAKT (Fig. 2A).
Since AKT/PKB is a cell survival pathway, we reasoned that
high pAKT levels in HCT-R cells may protect the cells not only
against apoptosis induced by HDACis, but also against other
apoptotic stimuli. To evaluate this possibility, we compared the
response of HCT-R cells and their HDACi-sensitive counterparts,
HCT-116 cells, to 5-fluorouracil (5-FU), a commonly used
chemotherapeutic agent for CC. The concentration of 5-FU
required for 50% growth inhibition has been reported for HCT-
116 cells, and drug-resistant cell lines derived from HCT-116 cells,
and is in the range of 0.09 mM to 2.4 mM [24]; therefore, we
analyzed the response of HCT-116 and HCT-R cells to 1.5 mM
5-FU (Fig. 2B). Treatment of HCT-116 cells with 5-FU resulted in
a significant decrease in the number of live cells from 86.76 8.3 to
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PLoS ONE | www.plosone.org 2 November 2011 | Volume 6 | Issue 11 | e27308Figure 1. HDACi-resistant HCT-R cells suppress Wnt/beta-catenin activity by overexpressing mediators of noncanonical Wnt
signaling. (A) Representative western blot analyses of CC cells and their conditioned media after exposure to mock treatment (M) or 5 mM butyrate
(B) for 19 hrs. (B and C). Silencing of WNT5A and ROR2 expression increases Wnt/catenin transcriptional activity of HCT-116 (B) and HCT-R (C) cells.
Cells (50,000/well) were co-transfected with reporters for Wnt/catenin transcriptional activity (TopFlash or FopFlash, 50 ng/well), pRL-TK as a control
for transfection efficiency, and control, ROR2,o rWNT5A siRNAs (10 pmol/well). Nucleic acids were introduced in the cells via a reverse transfection
protocol with Lipofectamine 2000 in 96-well plates. At 31 hrs post-transfection, cells were exposed for 20 hrs to mock (m) or 5 mM butyrate (b)
treatment. Wnt transcriptional activity was calculated as the ratio of the activity of TopFlash (with wild type Lef/Tcf binding sites) and FopFlash (with
mutant Lef/Tcf binding sites). Each transfection was performed in duplicate wells; data represent the mean from results of three experiments. (D).
Overexpression of WNT5A suppresses canonical Wnt transcriptional activity of HCT-116 cells. The co-transfection of HCT-116 cells (50,000/well) with
the Wnt activity reporters TopFlash or FopFlash (50 ng per well), and pcDNANeo3.1 or WNT5A-expressing construct (150 ng per well) were carried
Noncanonical Wnt Activity Mediates Drug Resistance
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did not significantly change the number of live cells. Thus, mock-
treated cells exhibited 95.862.1% live cells, and 5-FU - treated
cells exhibited 91.664.2% live cells, P.0.05 (Fig. 2B).
The possibility for a causal relationship between the increased
levels of pAKT and the expression of WNT5A and ROR2 was
tested via gene silencing and gene overexpression experiments.
Silencing of ROR2 expression in HCT-R cells by siRNA resulted
in a moderate decrease in pAKT levels, and the difference in
pAKT levels was statistically significant only between butyrate-
treated cells (Fig. 2C), The overexpression of WNT5A in HCT-
116 cells led to increased levels of pAKT, and the difference was
also statistically significant (Fig. 2D).
Additional studies with the human colon cancer cells SW620,
and the derived from them SW620R cells, that grow at 3 mM
butyrate, indicated that these cells do not express detectable levels
of ROR2 (data not shown); however, they express WNT5A, and
exposure to butyrate increases pAKT levels (Fig. 2E). Interestingly,
exogenous expression of WNT5A in SW620 cells suppressed Wnt/
beta-catenin dependent transcription even in the absence of
detectable ROR2 expression: in the presence of butyrate the Wnt
activity levels in WNT5A-expressing SW620 cells were 271632,
and the these in control-transfected cells were 389635 (Fig. 2F).
Therefore, in addition to ROR2, other receptors may mediate the
WNT5A signal, and the downstream activation of AKT kinase.
Suppression of pAKT levels augments the apoptotic
response of CC cells to HDACis
Since AKT signaling is a major cell survival pathway, we
reasoned that its suppression in CC cells exposed to HDACis
would augment the apoptotic effects of these agents. We utilized
MK2206, which is an allosteric inhibitor of AKT [25], and
determined that at 5 mM the agent suppresses pAKT levels in both
HCT-116 and HCT-R cells (Fig. 3A). To determine how Wnt/
beta-catenin signaling is affected by the AKT kinase inhibitor
MK2206 alone or in combination with a HDACi (butyrate or
LBH589), we analyzed the levels of transcriptionally active
(dephosphorylated) beta-catenin in HCT-116 cells treated for 8
or 17 hrs (Fig. 3B). At 8 hrs, HDACi-sensitive HCT-116 cells do
not exhibit signs of apoptosis, as ascertained by flow cytometry
analyses with Annexin V (data not shown); however, at 17 hrs
apoptosis is already detected and beta-catenin is cleaved at its N-
and C-terminus by caspases (see arrow on second panel of Fig. 3B).
Therefore, analyses of transcriptionally active beta-catenin levels
were carried out at 8 hrs in HCT-116 and HCT-R cells (Figs. 3B
and 3C). In both cell lines, MK2206 did not result in significant
changes in the levels of active beta-catenin compared to samples
treated with a HDACi alone; however, the levels of pAKT were
suppressed by MK2206 in all treatments (Fig. 3D).
To directly measure Wnt/beta-catenin transcription in cells
exposed to a pAKT inhibitor and/or HDACis, we transfected cells
with a reporter for Wnt/beta-catenin activity (TopFlash) or with a
control reporter (FopFlash) (Fig. 3E). The Wnt/catenin transcrip-
tional activity (TopFlash/FopFlash) in HCT-116 cells exposed to
mock or MK2206 treatment was 3.960.4 and 2.860.8, respectively
(P.0.05). In HCT-116 cells exposed to butyrate, or butyrate and
MK2206, the activity increased to 8.7362.9 and 12.861.3 (for both
treatments, P.0.05). Finally, when HCT-116 cells were exposed to
LBH589 or LBH589 and MK2206, the Wnt/beta-catenin activity
increased to 7.160.6 and 11.362.1, respectively, (P,0.05). In HCT-
R cells, exposure to mock, MK2206, butyrate, butyrate and
MK2206, LBH589, or LBH589 and MK2206 resulted in Wnt/
beta-catenin activity of 6.160.9, 4.661.2, 11.762.8, 16.062.9,
15.260.5, and 17.261.2, respectively, (P.0.05 for combinatorial
treatments compared to treatments with a HDACi alone). Thus,
MK2206 does not suppress the upregulation of Wnt transcriptional
activity by HDACis.
The combined effect of HDACis and MK2206 on apoptosis was
measured via flow cytometry analyses. Although there was no
statistically significant difference between the apoptotic levels in
mock and MK2206-treated cells, the addition of MK2206 to
butyrate or LBH589 resulted in a statistically significant increase
in apoptosis compared to treatment with each HDACi alone
(Fig. 3F). Thus, HCT-116 cells exposed to mock or MK2206
exhibited apoptotic levels of 12.862.2% and 14.363.5%,
respectively, (P,0.05). Treatment of HCT-116 cells with butyrate,
or butyrate and MK2206 resulted in 44.261.5% and 64.264.4%
apoptosis, respectively (P,0.05). In the presence of LBH589 or
LBH589 and MK2206, HCT-116 cells exhibited 55.766.9% and
73.564.7% apoptosis, respectively (P,0.05). In, HCT-R cells,
exposure to mock or MK2206 treatment resulted in 11.463.6%
and 11.064.0% apoptosis, respectively (P.0.05); exposure to
butyrate, or butyrate and MK2206 resulted in 14.463.6% and
25.264.1% apoptosis (P,0.05), and exposure to LBH589, or the
combination of LBH589 and MK2206 led to 31.665.3 and
45.764.4% apoptosis (P,0.05).
Currently, the pAKT inhibitor MK2206 is in a clinical trial for
colon cancers with wild-type KRAS; however, the combination of
a HDACi and a pAKT kinase inhibitor was highly effective in
inducing apoptosis in the HCT-116 cell line, which is KRAS-
mutant, and in re-sensitizing HCT-R cells to the apoptotic effects
of HDACis. To compare the efficiency of the drug combination in
CC cells with wild-type KRAS, we analyzed the apoptotic
response of the human colon cancer cells SW48 cells. SW48 cells
responded to the combination of a HDACi and MK2206 with
statistically significant increase in apoptosis (Fig. 3G): mock and
MK2206 treatments resulted in 16.660.7% and 16.960.7%
apoptosis, respectively (P.0.05). Treatment of SW48 cells with
butyrate, or butyrate and MK2206 resulted in 49.764.4 and
75.661.2% apoptosis, respectively (P,0.05), and exposure to
LBH589, or LBH589 and MK2206 resulted in 56.166.3% and
78.363.7% apoptosis, respectively (P,0.05). Western blot anal-
yses confirmed that MK2206 reliably suppressed the HDACi-
induced levels of pAKT in SW48 CC cells (Fig. 3H).
Diet-derived agents that mimic the effects of synthetic
HDACis and pAKT inhibitors
Whereas the combination of synthetic HDACis and pAKT
inhibitors could be applied in CC therapeutics or in prevention for
patients with increased risk for CC (e.g., patients with resected CC
out through a reverse transfection with Lipofectamine (0.7 ml/well) in 96-well plates. Post-transfection, cells were exposed to mock treatment (m) or
5 mM butyrate (b) for 20 hrs. Each transfection was performed in duplicate wells; data represent the mean from results of at least three experiments.
(E) Suppression of ROR2 expression increases the sensitivity of the HDACi-resistant HCT-R cells to the growth-suppressive effect of butyrate. HCT-R
cells (10
6) were nucleofected with 175 pmol of ROR2 (Invitrogen) or control siRNA, and 500,000 cells were plated per well in a 6-well plate. At 24 hrs,
cells were exposed to mock treatment (m) or 5 mM butyrate (b) for 17 hrs. At 48 hrs post-nucleofection, cells were plated at 100 or 200 per well in
triplicates. Percent clonal growth was calculated as the number of colonies arising from a single cell suspension of 100 cells. The experiment was
repeated three times and the results are the mean from the data of the three experiments. Statistically significant differences are noted by stars.
doi:10.1371/journal.pone.0027308.g001
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PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e27308Figure 2. HDACi-resistant HCT-R cells exhibit high expression levels of pAKT, a downstream effector of WNT5A and ROR2.
(A) HDACi-resistant HCT-R cells express higher levels of pAKT than HDACi-sensitive HCT-116 cells. Cells were plated in 6-well plates at 450,000 cells
per well, and at 24 hrs were exposed to mock (M) or 5 mM butyrate (B) treatment for 17 hrs. Total protein lysates were analyzed by western blot
analyses, and levels of Ser473-phosphorylated AKT (pAKT), total AKT(AKT), and ACTIN were detected as described in Materials and Methods. (B) HCT-R
cells are more resistant to 5-fluorouracil (5-FU) induced apoptosis than parental HDACi-sensitive HCT-116 cells. Cells were exposed to 1.5 mM 5-FU
for 24 hrs, and apoptotic assays were performed as described in Materials and Methods. Percentage of live cells was calculated by dividing the
number of live cells by the total number of analyzed cells. (C) Silencing of ROR2 expression in HCT-R cells decreases the levels of Ser473-
phosphorylated AKT. One-million cells were nucleofected with control or ROR2 siRNAs (175 pmol, Invitrogen), and plated at 500,000 per well in 6-well
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with HDAC- and pAKT-inhibitory functions could become a CC
prevention approach for the general population. Since butyrate is
the most potent diet-derived HDACi produced in the colon [26], a
CC-preventive diet should contain sufficient levels of fermentable
fiber. To find a pAKT inhibitor that can be derived from diet, we
performed a literature search and found publications on
sulforaphane, natural sphingadienes, garlic-derived diallyl trisul-
fide (DATS), caffeic acid phenethyl ester (CAPE, from honeybee
propolis), curcumin, and resveratrol, all of which inhibit pAKT
levels in different cell types [27–33]. We tested some of these
compounds for their ability to suppress the levels of butyrate-
induced pAKT in CC cells, and found that CAPE, DATS, and
sulforaphane suppressed the increase of pAKT kinase levels in
butyrate-treated HCT-116 cells, and only CAPE and DATS were
active in HCT-R cells (Fig. 4A). Of the three compounds tested,
CAPE was most powerful in suppressing the butyrate-induced
levels of pAKT in both cell types; however, it did not induce
apoptosis in either of these cells by itself (Fig. 4B). Thus, in HCT-
116 cells, mock exposure and treatment with 4 mg per ml CAPE
resulted in 12.263.1% and 11.960.8% apoptosis, respectively;
exposure to butyrate or the combination of butyrate and CAPE
resulted in 44.861.8% and 78.466.5% apoptosis, respectively
(P,0.05). In HCT-R cells, mock exposure, treatment with
butyrate, and treatment with CAPE alone resulted in 8.961.2%,
12.661.7%, and 10.963.0% apoptosis, respectively (P.0.05).
However, when HCT-R cells were exposed to the combination of
CAPE and butyrate, the apoptotic levels increased by almost
three-fold, to 30.663.6% (P,0.05) (Fig. 4B). Subsequent analyses
revealed that in butyrate-treated HCT-R cells, CAPE suppresses
the phosphorylated levels of the p55 subunit of phosphatidyl-
inositol-3 kinase (PI3K), a major upstream activator of AKT
kinase (Fig. 4C). However, the precise step at which this
suppression takes place is not known, and it is a focus of future
research. We did not detect consistent suppression of the phospho-
p55 PI3K levels in HCT-116 cells exposed to CAPE and butyrate
(data not shown).
Discussion
The World Cancer Research Fund/American Institute for
Cancer Research’s Continuous Update Project has just recently
upgraded the protective role of dietary fiber against colorectal
cancer from "probable" to "convincing" [34]. The protective role
of fiber against CC is most likely mediated by its fermentation
product in the colon, butyrate. However, we have observed that
prolonged exposure of CC cells to low concentrations of butyrate
may result in acquisition of butyrate resistance, and cross-
resistance to structurally unrelated HDACis as well as to 5-FU.
Thus, butyrate-resistant HCT-R cells, derived from butyrate-
sensitive HCT-116 CC cells, are cross-resistant to LBH589,
MS275, SAHA, TSA, and 5-FU [9, and Fig. 2B]. Here we report
that the exposure of CC cells to butyrate increases the expression
of WNT5A and WNT11, and that HDACi-resistant HCT-R cells
exhibit higher expression levels of these WNT ligands than their
HDACi-sensitive counterparts, HCT-116 cells (Fig. 1A). HCT-R
cells also express higher levels of the WNT5A receptor ROR2
(Fig. 1A). Both WNT5A and WNT11 can activate noncanonical
Wnt signaling, and WNT5A does this through the ROR2
receptor. Thus, in the presence of the tyrosine kinase receptor
ROR2, WNT5A inhibits canonical Wnt signaling [13–15];
however, in the presence of the receptors FRIZZLED 4 or
FRIZZLED 5 and LRP5 or LRP6, WNT5A activates beta-
catenin–dependent Wnt signaling [15–17].
It has been established that noncanonical Wnt signaling
counteracts the levels of the canonical Wnt pathway [35,36],
and we have demonstrated that the relatively high fold induction
of canonical Wnt signaling is necessary for significant apoptotic
effects of butyrate in CC cells [8,9]. Therefore, the increased
expression of mediators of noncanonical Wnt signaling (e.g.,
WNT5A, WNT11, and ROR2) in HCT-R cells may explain the
resistance of the cells to butyrate-induced apoptosis. In agreement
with this possibility, the decreased expression of WNT5A and its
receptor, ROR2 resulted in increased canonical Wnt-dependent
transcription in CC cells exposed to butyrate (Figs. 1B and 1C).
Furthermore, the exogenous expression of WNT5A in HCT-116
cells that express lower levels of this ligand compared to HCT-R
cells resulted in suppression of canonical Wnt transcription
(Fig. 1D). Silencing of ROR2 expression in HCT-R cells increased
Wnt/beta-catenin signaling levels (Fig. 1C), and re-sensitized the
cells to the growth inhibitory effect of butyrate (Fig. 1E). The
moderate effect of the suppressed ROR2 levels on clonogenicity of
HCT-R cells (Fig. 1E) may be due to (1) the moderate suppression
of ROR2 expression by siRNA (Fig. 2C), (2) the ability of WNT5A
to affect canonical Wnt levels through receptors other than ROR2
[37], and (3) the additional suppression of canonical Wnt
transcription by WNT11 and other WNT ligands that are not
mediated by ROR2.
WNT5A activates two survival pathways: SRC/ERK and
AKT/PKB signaling [38]. The activation of AKT kinase signaling
by HDACis has been observed in small cell lung cancer and
rodent embryonic fibroblasts [39–41]; however, the mechanism
underlying this effect has not been elucidated. Here we
demonstrate that butyrate increases pAKT levels in CC cells in
part through the noncanonical activity of WNT5A. Consistent
with the higher expression levels of WNT5A and ROR2 in HCT-
R cells, these cells exhibit higher levels of pAKT than the HDACi-
sensitive HCT-116 cells (Fig. 2A). A similar increase in WNT5A
and pAKT levels was observed in another pair of CC cell lines:
SW620 cells and their butyrate-resistant counterparts, SW620R
cells that grow at 3 mM butyrate (Fig. 2E). The increase in pAKT
levels in butyrate-resistant HCT-R cells suggested that these cells
may resist the apoptotic effect of not only HDACis, but that of
other pro-apoptotic stimuli. This possibility was confirmed by
comparative apoptotic analyses of HCT-116 and HCT-R cells
exposed to 5-FU (Fig. 2B).
plates. At 24 hrs post-transfection, the cells were exposed to mock (M) or 5 mM butyrate (B) for 19 hrs. Total cell lysates were analyzed by western
blot; a representative western blot is shown. The bar graph under the western blot image represents the quantification of pAKT levels in three
independent experiments by densitometry, the difference between butyrate-treated cells are statistically significant (P,0.05), (D).Overexpression of
recombinant WNT5A in HCT-116 cells results in increased pAKT levels. HCT-116 cells were transfected with an empty vector or a WNT5A expression
vector, and selected for stable expression of these constructs. Duplicate samples were analyzed for expression levels of WNT5A and pAKT as
described above; a representative western blot is shown. The bar graph under the western blot represents the quantification of pAKT in three
independent experiments by densitometry, P,0.05. (E) Representative western blot analysis of SW620 human CC cells and SW620R cells that grow at
3 mM butyrate. The two cell lines were exposed to mock (m) or 5 mM butyrate (b) treatment for 17 hrs and analyzed as in Fig.2A. (F). SW620 cells
expressing exogenous WNT5A exhibit suppressed induction of Wnt/beta-catenin transcription by butyrate, P,0.05. Transfection and analyses were
performed as described in Fig. 1D.
doi:10.1371/journal.pone.0027308.g002
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PLoS ONE | www.plosone.org 7 November 2011 | Volume 6 | Issue 11 | e27308Figure 4. Diet-derived pAKT inhibitors mimic the effects of MK2206 in augmenting HDACi-induced apoptosis in CC cells. (A) Diet-
derived compounds suppress butyrate-induced pAKT levels in CC cells. Representative western blot of cells exposed for 14 hrs to mock treatment
(M), 5 mM butyrate (B), 5 mM butyrate and 4 mg/ml CAPE (BC), 5 mM butyrate and 20 mM sulforaphane (BS), 5 mM butyrate and 40 mM DATS (BD).
Detection of pAKT, total AKT (AKT), and ACTIN was carried out with total cells lysates. (B) Apoptotic levels in HCT-116 and HCT-R cells exposed for
28 hrs to mock treatment (M), 4 mg/ml CAPE (C), 5 mM butyrate (B), or butyrate and 4 mg/ml CAPE (BC). Apoptotic assays were performed by flow
cytometry. Percent apoptosis and necrosis was calculated by dividing the number of apoptotic and necrotic cells by the total number of analyzed
cells. Each experiment had triplicate samples per treatment; data represent the mean of three experiments. Statistically significant differences
(P,0.05) are noted by a star. (C) CAPE suppresses the phospho-p55 PI3K levels in butyrate-treated HCT-R cells. Cells were treated as in (B) for 17 hrs,
and total cell lysates were analyzed by western blotting. Phospho-p85 levels were not detected; however, phospho-p55 levels were detected and the
bar graph next to the western blot represents the densitometry quantification of phospho-p55 PI3K in three independent experiments.
doi:10.1371/journal.pone.0027308.g004
Figure 3. Simultaneous increase in canonical Wnt signaling and suppression of pAKT result in increased apoptosis of CC cells.
(A) Suppression of pAKT levels in CC cells by the allosteric inhibitor MK2206. Representative western blot analysis of CC cells exposed for 17 hrs to
mock (M), 5 mM butyrate (B), butyrate and 1 mM MK2206 (MK1B), or butyrate and 5 mM MK2206 (MK5B). (B) The steady-state levels of
transcriptionally active beta-catenin are not decreased in HCT-116 cells by combined treatment with a HDACi and MK2206. Cells were exposed for 8
or 17 hrs to mock treatment (M), 5 mM butyrate (B), butyrate and 5 mM MK2206 (BMK), 100 nm LBH589 (L), or 100 nm LBH589 and 5 mM MK2206
(LMK). Total cell lysates were analyzed for steady-state levels of total and Ser37/Thr41 dephosphorylated beta-catenin. Representative western blot
analysis is shown. (C) Active beta-catenin levels in HCT-R cells exposed for 8 hrs to mock (M), 5 mM butyrate (B), butyrate and 5 mM MK2206 (BMK),
100 nm LBH589 (L), or 100 nm LBH589 and 5 mM MK2206 (LMK). (D) Representative western blot analysis of Ser473-phosphorylated AKT (pAKT) and
total AKT (AKT) levels in CC cells exposed for 17 hrs to mock (M), 5 mM butyrate (B), butyrate and 5 mM MK2206 (BMK), 100 nm LBH589 (L), or 100 nm
LBH589 and 5 mM MK2206 (LMK). (E) The induction of Wnt/catenin-dependent transcriptional activity (TopFlash/FopFlash) in CC cells by a HDACi
(butyrate or LBH589) is not suppressed by a pAKT inhibitor. Cells were nucleofected at one million with 1 mg of plasmid (TopFlash or FopFlash) and
pRL-TK, diluted, and plated at 30,500 cells per well in 96-well plates. At 24 hrs post-nucleofection, cells were treated for 8 hrs with mock (M), 5 mM
butyrate (B), butyrate and 5 mM MK2206 (BMK), 100 nm LBH589 (L), or 100 nm LBH589 and 5 mM MK2206 (LMK). Data represent the mean from
results of at least three experiments. Statistically significant differences are noted by a star. (F) Apoptotic levels in HCT-116 and HCT-R cells exposed to
HDACis and a pAKT inhibitor. The cells were exposed for 28 hrs to: mock treatment (M), 5 mM butyrate (B), butyrate and 5 mM MK2206 (BMK),
100 nm LBH589 (L), or 100 nm LBH589 and 5 mM MK2206 (LMK). Percent apoptosis and necrosis was calculated by dividing the number of apoptotic
and necrotic cells by the total number of analyzed cells. Each experiment had triplicate samples per treatment; data represent the mean of three
experiments. Statistically significant differences are noted by a star. (G, H) SW48 human CC cells with wild type KRAS are as sensitive as HCT-116 cells
with mutant KRAS to the combined treatment with a HDACi and a pAKT inhibitor. SW48 cells were treated and analyzed as described in Figs.3D and
3F. Representative western blots and apoptotic data, representing the mean of three experiments, are shown. Statistically significant differences are
noted by a star.
doi:10.1371/journal.pone.0027308.g003
Noncanonical Wnt Activity Mediates Drug Resistance
PLoS ONE | www.plosone.org 8 November 2011 | Volume 6 | Issue 11 | e27308The increased levels of pAKT were in part dependent upon the
expression of ROR2 and WNT 5A, since silencing of ROR2
expression decreased the levels of pAKT kinase in HCT-R cells
(Fig. 2), and overexpression of WNT5A increased the levels of
active AKT in HCT-116 cells (Fig. 2D). Therefore, the resistance
of HCT-R CC cells to apoptosis is mediated in part by the high
expression levels of WNT5A. A similar anti-apoptotic function of
this WNT ligand has been described in other experimental
models. Treatment of lung fibroblasts with WNT5A increased
their proliferation and resistance to H2O2-induced apoptosis, and
this effect was not mediated through the Wnt/beta-catenin
pathway [42]. In osteoblastic cells, serum withdrawal-induced
apoptosis was also prevented by WNT5A, and concurrent with
our results, beta-catenin transcriptional activity was dispensable
for the anti-apoptotic function of WNT5A [38]. Analyses of
additional pair of colon cancer cells lines, SW620 cells and the
derived from them SW620R cells, that grow at 3 mM butyrate,
revealed that both cell lines do not express detectable levels of
ROR2 (data not shown); however, they express WNT5A, and
increase the levels of pAKT in the presence of butyrate (Fig. 2E).
The overexpression of WNT5A in butyrate-treated SW620 cells
suppressed Wnt/beta-catenin dependent transcription, indicating
that the suppressive effect of WNT5A on canonical WNT
signaling can be mediated by receptors other than ROR2.
Therefore, the activation of pAKT in human CC cells is only in
part mediated by WNT5A/ROR2 signaling.
The increased expression of WNT ligands in CC cell
populations exposed to butyrate (Fig. 1A) may contribute to
compensatory proliferation, a phenomenon first described in
Drosophila. Thus, in apoptotic cells of proliferating Drosophila tissues,
a caspase-dependent mechanism triggers the secretion of the
mitogens Decapentaplegic, a homolog of the mammalian
TGFbeta/BMP ligand family), and Wingless, a homolog of the
mammalian WNT ligands [43–45]. Compensatory proliferation is
detected even in Drosophila differentiated tissues, where the
apoptotic cells mediate the activation of Hedgehog signaling in
the surviving cells [46]. Therefore, the increased expression of Wnt
ligands, and the subsequent increase in pAKT levels in butyrate-
treated CC cells, may represent a survival mechanism in
mammalian cells exposed to pro-apoptotic stimuli. Other reports
support this hypothesis; thus, apoptosis-inducing treatments such
as chemotherapeutic agents, radiation, and nutrient deprivation,
all trigger increase in pAKT levels, and it would be of interest to
ascertain whether this increase is due to the secretion of WNT5A
and/or other Wnt ligands by the apoptotic cells [25,47–49]. If this
is the case, apoptosis in cancer cells can be augmented by
combining pro-apoptotic agents with repressors of noncanonical
Wnt signaling, and/or inhibitors of the survival pathways induced
by noncanonical Wnt activity.
Since exposure of CC cells to HDACis augments the pAKT
levels, we reasoned that inhibition of AKT kinase may augment
the apoptotic effects of butyrate and synthetic HDACis. We
achieved a reliable inhibition of pAKT levels in HCT-116 and
HCT-R cells with 5 mM of MK2206, an allosteric inhibitor of
AKT kinase [25], Fig. 3A. The effect of MK2206 on canonical
Wnt activity was tested by analyzing the steady-state levels of
transcriptionally active beta-catenin (Figs. 3B and 3C), and by
measuring beta-catenin - dependent transcription with reporter
vectors (Fig. 3E). Although the induction of Wnt/catenin-
dependent activity by HDACis was not changed significantly by
MK2206, the induction of pAKT by HDACis was suppressed
(Figs. 3B-E). The suppression of HDACi-induced pAKT correlat-
ed with the increased apoptotic effect of HDACis in the presence
of MK2206 (Fig. 3F); however, the suppression of pAKT in
absence of HDACis did not affect apoptosis. In addition to re-
sensitizing HDACi-resistant HCT-R cells to the apoptotic effects
of butyrate and LBH589 (Fig. 3F), MK2206 also augmented the
apoptotic effects of butyrate and LBH589 in SW48 human CC
cells (Figs. 3G and 3H). If, as discussed above, all pro-apoptotic
stimuli upregulate pAKT levels, treatments with any apoptosis-
inducing anti-cancer drug would benefit by combined application
with pAKT inhibitors. In agreement with this hypothesis, in lung
and ovarian tumor cells, MK-2206 synergistically inhibited cell
proliferation when combined with an array of anti-cancer agents
(e.g., erlotinib, lapatinib, topoisomerase inhibitors, antimetabolites,
anti-microtubule agents, and DNA cross-linkers) [25].
The transition from canonical to noncanonical Wnt signaling is
frequently a hallmark of later stages of neoplastic development
[50]. Thus, WNT5A expression is elevated in CCs compared to
normal colon and during the progression from adenoma to
carcinoma [51,52]. The increase in noncanonical Wnt activity
likely causes the increased pAKT levels that are also observed
during the transitions from normal mucosa to colorectal cancer,
and primary tumors to metastases [53,54]. Since late stage CCs
are characterized by increased levels of noncanonical Wnt
signaling, therapeutic regimens that combine HDACis and pAKT
suppressors may be more effective than HDACis alone. However,
early stage colonic neoplasms might be also effectively suppressed
by regimens combining HDACis and pAKT inhibitors, and this
approach can be utilized in CC prevention. This possibility
prompted us to explore combinations of agents that are diet-
derived and replicate the concept established with LBH589 and
MK2206, i.e., simultaneous increase in canonical Wnt signaling
and decrease in AKT kinase signaling. We tested several reported
diet-derived pAKT inhibitors for their ability to suppress butyrate-
induced levels of pAKT in HCT-116 and HCT-R cells, and found
that CAPE, DATS, and sulforaphane suppressed to a different
extent the induction of pAKT (Fig. 4A). From the three
compounds, sulforaphane (20 mM) did not inhibit the butyrate-
increased levels of pAKT in HCT-R cells (Fig. 4A). The
combination of butyrate and CAPE, a compound contained in
dietary supplements of honeybee propolis, replicated the apoptotic
effects of the combination of synthetic drugs LBH589 and
MK2206 (Fig. 4B). Similarly to MK2206, CAPE did not induce
apoptosis in CC cells when utilized alone; however, it significantly
upregulated the apoptotic levels in cells exposed to butyrate
(Fig. 4B). In butyrate-treated HCT-R cells CAPE suppressed the
levels of phospho-PI3K (Fig. 4C), the major upstream activator of
AKT kinase; however, no consistent effect was observed in HCT-
116 cells (data not shown). These results are congruent with the
fact that in HCT-R cells the expression levels of WNT5A and
ROR2 are higher than in HCT-116 cells (Fig. 1A), and therefore,
changes in the activation status of PI3K are easier to detect.
In our analyses, we utilized CAPE at 4 mg per ml (14 mM),
DATS at 40 mM, and sulforaphane at 20 mM. The bioavailability
of these compounds in the human colon is not well established;
however, it has been reported that the maximum concentration of
CAPE in human serum is 5 mg/ml [55]; whereas, sulforaphane
reaches up to 40 mmol in murine intestine and colon target tissue
[56,57]. DATS, a component of garlic, was utilized at 40 mM, a
concentration that likely exceed the levels achievable in vivo;
however, in addition to DATS, other garlic-derived compounds
exhibit pAKT inhibitory function [58]; therefore, the combined
effect of all compounds contained in garlic on the pAKT levels
might be additive. Additive or synergistic effect on the pAKT
levels might be also expected by the combined intake of CAPE,
DATS, and sulforaphane, if these diet-derived compounds inhibit
pAKT through different mechanisms. For example, CAPE inhibits
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ulates pAKT levels by inhibiting ROR2, a tyrosine kinase. On the
other hand, the soy sphingadienes, other diet-derived pAKT
inhibitors, may interfere with the translocation of AKT kinase to
the membrane [27]. Thus, the simultaneous intake of several diet-
derived weak pAKT inhibitors from soy, garlic, cruciferous
vegetables, and wine may result in colonic contents with
resveratrol, sulforaphane, diallyl trisulfide, and sphingadienes, all
of which are reported to inhibit pAKT [27–33], and such
combination may result in the additive or synergistic inhibition of
pAKT . Whereas individual diet-derived pAKT inhibitors have
decreased significantly the tumor formation in Min/+ mice, a
model for intestinal cancer [61]; the anti-neoplastic potential of
combinations of diet-derived butyrate and pAKT inhibitors has
not been assessed. Future experiments are necessary to determine
the most effective food combinations that result in hyper-activation
of canonical Wnt signaling and suppression of pAKT in CC cells.
Such studies may result in the design of CC-preventive diets.
Finally, our results may in part explain why fiber supplements are
not as effective as diet-derived fiber in preventing development of
colonic neoplasms [62]; thus, unlike fiber supplements, dietary
fiber is usually accompanied by compounds that suppress pAKT
activity (e.g., sulforaphane from cruciferous vegetables, DATS
from garlic, etc.).
The concept of targeting two signaling pathways (hyper-
induction of canonical Wnt signaling and suppression of AKT
signaling) might be effective not only in prevention and therapy of
CC, but also in these of other types of cancer. For example, in
melanoma WNT5A promotes the metastatic potential of the cells
[63], antagonizes Wnt/catenin signaling at later stages, and
contributes to cell proliferation [64]. Similarly, ROR2 functions as
a survival kinase that contributes to the resistance of HeLa cervical
carcinoma cells to apoptosis [65], and it has been proposed as a
target for melanoma and osteosarcoma therapy [63,66]. These
data have led to the re-evaluation of the oncogenic role of Wnt/
catenin signaling in different types of cancer, including colon
cancer [67].
Materials and Methods
RNA isolation, PCR array, data analysis
Total RNA was isolated from HCT-116 and HCT-R CRC cells
treated with 5 mM butyrate for 24 hrs or mock treated utilizing
the RNAeasy kit (Qiagen) coupled with RNase-free DNAse
digestion (Qiagen) according to manufacturer’s instructions.
Subsequent to isolation, RNA was tested for integrity and overall
quality by spectrophotometric analyses, as well as agarose gel
electrophoresis. At least 5 mg of each sample was sent to SA
Biosciences for analysis. A total of four replicates were performed.
Data analysis was performed by SA Biosciences, and the following
comparisons of gene expression were evaluated: HCT116
butyrate-treated vs. mock, HCR-R mock vs. HCT-116 mock,
HCT-118 butyrate-treated vs. HCT-R butyrate-treated, and
HCT-R butyrate-treated vs. HCT-R mock. P values for each
comparison for each gene expression profile comparison was
determined, and statistically significant (P,0.05) changes in gene
expression of two-fold or more were considered relevant for
subsequent follow-up analyses.
Cell culture, recombinant plasmids, and chemicals
Human CC cell lines HCT-116 and SW620 were obtained
from the American Type Culture Collection (Rockville, MD). The
cell lines HCT-R and SW620-R were derived from HCT-116 and
SW620 cells, respectively, by culturing the parental cells in
increasing concentrations of butyrate, as previously described [9].
All cell lines were grown in alpha-MEM with 10% fetal bovine
serum. The following vectors were kind gifts: WNT5A expression
vector (Dr. A. K. Rustgi, University of Pennsylvania, Philadel-
phia), pTOPFLASH (TOP) and pFOPFLASH (FOP), (Dr. H.
Clevers, UMC Utrecht, Utrecht, Netherlands). The following
chemicals were obtained from different companies: sodium
butyrate (Sigma, St. Louis, MO), MK2206 (Selleck Chemicals),
LBH589 (Novartis), caffeic acid phenethyl ester, diallyl trisulfide,
and sulforaphane (Santa Cruz Biotechnology).
Transfections
Transfections were performed with Lipofectamine 2000 (Life
Technologies, Rockville, MD) or via nucleofection with Amaxa
(Lonza). We applied the reverse Lipofectamine transfection
protocol, according to which complexes between DNA and
Lipofectamine are pre-formed in a 96-well plate format, and
50,000 cells were added per well. Silencing of WNT5A, and ROR2
gene expression was achieved with siRNAs from Santa Cruz
Biotechnology and Invitrogen. The vector pRSV-TK (Promega
Corp., Madison, WI) was used for normalization of transfection
efficiency in luciferase reporter assays, which were performed
using a Turner Luminometer and a Dual Luciferase kit (Promega,
Madison, WI).
Clonal growth assays
Clonal growth assays were performed as described previously
[8]. For these assays, HCT-R cells were nucleofected with ROR2
siRNAs, and at five hours were mock treated or exposed to 5 mM
sodium butyrate treatment for 17 hrs. Equal numbers of cells from
each treatment were plated in triplicates in 6-well dishes. Fourteen
days later the colonies were stained with crystal violet solution and
their numbers determined. The percentage clonal growth is the
number of colonies that grew from 100 plated cells.
Western blot analyses and antibodies
Cells were plated in 6-well plates at 450,000 cells per well, and
24 hrs after plating were exposed to treatments for 17 hrs. Total
cell lysates were obtained as described previously [68]. Equal
amounts of protein were subjected to SDS-polyacrylamide gel
electrophoresis (SDS-PAGE), transferred to nitrocellulose, and
immunostained with antibodies against WNT5A, WNT11,
Ser473-phosphorylated AKT, total AKT, beta-catenin (all from
Santa Cruz Biotechnology), or ACTIN (A5441, Sigma). ROR2
was detected with a Santa Cruz Biotechnology antibody (sc-98486)
or with a mouse monoclonal antibody to the carboxy-terminal
part of ROR2, encoded by bases 2535–2835 of the mouse ROR2
[69]. The mouse anti-ROR2 antibody was a gift from Dr. R.
Nusse (Stanford University, Stanford), and it is currently available
from the Development Studies Hybridoma Bank at the University
of Iowa. The form of transcriptionally active beta-catenin that is
dephosphorylated on Ser37 or Thr41 was detected with anti-ABC,
clone 8E7, from Millipore. Phospho-PI3K p85 (Tyr458)/p55
(Tyr199) antibody that detects endogenous levels of p85/p55 only
when phosphorylated at tyrosine 458/tyrosine 199 was purchased
from Cell Signaling. Western blots were visualized with a species-
specific secondary antibody conjugated to horseradish peroxidase
(Sigma) and a chemiluminescence reagent (PerkinElmer Life
Sciences, Boston, MA). To detect secreted WNT5A and WNT11,
HCT-116 and HCT-R cells were grown in 15-cm dishes, and
exposed to mock or 5 mM butyrate treatment for 19 hrs in
medium with 2% FBS. The conditioned medium was harvested,
any detached cells were removed by centrifugation, and CHAPS
was added to 0.1%. Proteins in the medium were precipitated for
Noncanonical Wnt Activity Mediates Drug Resistance
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trichloroacetic acid. After centrifugation at 10,000g for 10
minutes, pellets were resuspended in Laemmli buffer, and
analyzed via western blot with a mouse WNT5A antibody or a
rabbit WNT11 antibody (sc-365370 and sc-116–210, Santa Cruz
Biotechnology). Densitometry was performed using an Alpha
Innotech MultiImage II (auto background) , normalizing for
differences in ACTIN values, and for differences in film to film
exposure intensity.
Apoptotic assays
CC cells were plated 24 hrs prior to analyses in 24-well plates at
110,000 to 140,000 cells per well, and exposed to treatments for
27 hrs. All cells (floating and attached) were harvested and stained
for apoptotic and necrotic markers with PE Annexin V Apoptosis
Detection Kit I (BD Biosciences, #559763). Flow cytometry
analyses were carried out with FACS Aria II and DiVa software.
Statistics
All data were presented as mean 6 standard deviation from at
least three sets of independent experiments. Student T-test analysis
was used to determine the significance of statistical differences.
Differences were considered significant at P,0.05.
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